Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
35 results about "Glial scar" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Glial scar formation (gliosis) is a reactive cellular process involving astrogliosis that occurs after injury to the central nervous system. As with scarring in other organs and tissues, the glial scar is the body's mechanism to protect and begin the healing process in the nervous system.
Fibroin three-dimensional bracket for nervus centralis remediation
InactiveCN106668950AUnique Mechanical PropertiesAdequate physical supportTissue regenerationProsthesisHuman bodyCell-Extracellular Matrix
The invention relates to a fibroin three-dimensional bracket for nervus centralis remediation, and belongs to the field of biological medicinal materials. The fibroin three-dimensional bracket comprises fibroin protein fiber with grooves, fibroin protein / hyaluronic acid plural gel and fibroin membrane conduits. By adopting the fibroin three-dimensional bracket, defects that a conventional bracket is low in mechanical property, low in biodegradability and the like are overcome. By adopting the fibroin three-dimensional bracket, physiological states of an extracellular matrix can be simulated, adhesion, migration, amplification and differentiation of cells can be facilitated, and furthermore orientated growth of axon to fracture parts can be guided; due to connection of the bracket, glial scars can be inhibited, and thus remediation of a nervus centralis system can be facilitated; and the bracket can be applied to basic research on neural injury remediation, can be also applied to bridging remediation of human body spinal cord injury or deficiency, and has good biomedical prospects.
Owner:WUHAN TEXTILE UNIV
Application of miR containing 5'- terminal specific seed base sequence, improved Schwann cell and applications thereof
ActiveCN109694882AAchieve regenerationEnhance cell propertiesNervous disorderGenetically modified cellsNeurotrophic factorsExpression gene
The invention provides an application of a miR containing a 5'- terminal specific seed base sequence, an improved Schwann cell and applications thereof, and relates to the technical field of central nervous system damage repairing. The miR is used to promote the compatibility and integration between Schwann cells and astrocyte; and the 5'- terminal specific seed base sequence is UAAGGCAC or AAGGCAC. The results of experiments show that after the expression level of matured miR containing a 5'- terminal specific seed base sequence is artificially improved, the expression of astrocyte related gene in improved Schwann cells is obviously reduced, the expression of neurotrophic factor genes (NT-3 and BDNF) is obviously increased, and improved Schwann cells are compatible with and fused with astrocyte. The improved Schwann cells can inhibit astrocyte, the integration of Schwann cells and astrocyte is promoted, and the formation of glial scars caused by astrocyte is inhibited.
Owner:JILIN UNIV
Neuronal regeneration promoting agent
InactiveUS20100292454A1Efficient deliveryEasy to degradeOrganic active ingredientsSugar derivativesMorphogenesisBULK ACTIVE INGREDIENT
It is an object of the present invention to provide a novel neuronal regeneration promoting agent, particularly a neuronal regeneration promoting agent having an inhibitory effect on glial scar formation. The present invention provides a neuronal regeneration promoting agent which comprises an inhibitor of a bone morphogenetic protein type 1A receptor (BMPR1A) as an active ingredient.
Owner:RIKEN +2
Precision mouse spinal cord clamping injury clamp and clamping injury force adjusting method
InactiveCN103989536AEasy to adjustFlexible and convenient intensity adjustmentSurgical veterinaryOsteotomyGlial scar
The invention relates to the field of machines, in particular to a precision mouse spinal cord clamping injury clamp and clamping injury force adjusting method. The distance between the abutting side of the clamp and the clamping penetrating side of the clamp is adjusted by screwing in or screwing out an abutting screw so as to adjust the clamping force. The method comprises the following steps of selecting a female mouse with the weight ranging from 18 g to 21 g, precisely positioning the eleventh vertebral body of the mouse, conducting an osteotomy on the back vertebral plate of the vertebral body, and clamping the segment of the spinal cord to be injured in the left-right direction with a special improved vascular clamp, so that molding is successful. Compared with the prior art, the method for building the spinal cord injury model is simple and easy to implement, precise, easy to repeat, high in success rate and the like. After an injury, behavior indicators, spinal cord injury pathological indicators and glial scar indicators are observed, the method can well simulate the real process formed after the human spinal cord injury, the simulation degree is quite high, the real process is highly reproduced, and the method has the advantages beyond comparison with existing methods.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Treating Gliosis, Glial Scarring, Inflammation or Inhibition of Axonal Growth in the Nervous System by Modulating Eph Receptor
InactiveUS20080254023A1Prevent and decrease gliosisPrevent and decrease and glial scarringNervous disorderPeptide/protein ingredientsMedicineAxon Outgrowth
The present invention relates to a method of treating disorders of the nervous system and more particularly disorders associated with a gliotic response and / or an inflammatory response within the central nervous system and to therapeutic agents useful for same. More particularly, the present invention involves a method of preventing or reducing the amount of Eph receptor-mediated gliosis and / or glial scarring and / or inflammation and / or Eph receptor-mediated inhibition of axonal growth which occurs during and / or after disease or injury to the nervous system. The present invention also facilitates the identification of therapeutic agents which modulate Eph receptor-mediated signaling. The method and therapeutic agents of the present invention are useful for treating a range of nervous system diseases, conditions and injuries including, inter alia, paralysis induced by physiological-, pathological- or trauma-induced injury to the brain or spinal cord.
Owner:THE UNIV OF QUEENSLAND +1
Application of Adjudin in preparing medicine for inhibiting glial scar formation
InactiveCN106344573AReduce sizeImprove behaviorOrganic active ingredientsNervous disorderInjury brainAdjudin
The invention belongs to the field of medicine preparation, and particularly relates to application of Adjudin in preparing medicine for inhibiting glial scar formation. The glial scar is formed by activation and proliferation of astrocyte after central lesion. The medicine is at least in a form of tablets, capsules, granules, dripping pills, suspensions, syrup, enteric-coated preparation, emulsion suspension and injections. Experiments show that Adjudin can effectively reduce size of the glial scar of mice after brain tissue injury; in an in-vitro primary cell scratch model, Adjudin remarkably inhibits proliferation and migration of astrocyte cells, improves ethology of the mice after brain injury and promotes recovery, so that Adjudin has important application value in preparing the medicine for inhibiting glial scar formation.
Owner:SHANGHAI JIAO TONG UNIV
Pharmaceutical application of nafamostat
ActiveCN103479612AImprove BBB ratingReduce apoptosisOrganic active ingredientsNervous disorderApoptosisMethylprednisolone
The invention provides application of nafamostat in preparation of a medicament for treating spinal cord injury. The nafamostat is applied to therapeutic intervention of the spinal cord injury, and experiments show that the nafamostat can reduce apoptosis of cells, promote survival of neurons, inhibit formation of glial scars and remarkably improve the BBB score of a treated animal. Compared with a methylprednisolone medicament applied clinically at present, the nafamostat has the advantages of wider administration window, more lasting treatment effect and better long-term effect.
Owner:冯世庆
Application of compound to repair of nerve damage
ActiveCN106822136AImprove BBB ratingReduce the level of apoptosisOrganic active ingredientsNervous disorderMedicineApoptosis
Owner:冯世庆 +1
Preparation method of human oligodendrocyte precursor cell inhibiting nerve secondary injury, kit and application thereof
ActiveCN106011173AInhibition of secondary damageProtect physiological functionNervous disorderNeuregulinsVirus typeGlial Growth Factor
The invention provides a preparation method of a human oligodendrocyte precursor cell inhibiting nerve secondary. Specifically, the method includes: constructing a virus expression vector of two glial growth factors, conducting cotransfection of a human oligodendrocyte precursor cell to prepare the human oligodendrocyte precursor cell, which can achieve high expression of the two glial growth factors, i.e. a growth related factor 43 and a glial growth factor 2, give play to the combined action of the two to promote oligodendrocyte repair, and inhibit nerve secondary injury caused by proliferative response and glial scar formation after oligodendrocyte injury. Also, the proliferation and differentiation ability of oligodendrocyte precursor cell itself is also utilized to participate in nerve function repair, and no tumorigenesis exists. The invention also provides a kit for preparation of the human oligodendrocyte precursor cell inhibiting nerve secondary. The human oligodendrocyte precursor cell provided by the invention has very good therapeutic effect on nervous system diseases.
Owner:江西美奥生物技术有限公司
In-vitro glial scar forming model and establishment method and application thereof
ActiveCN104911140AEasy to observeEasy to makeMicrobiological testing/measurementNervous system cellsSmall cellCell growth
The invention belongs to the technical field of cytobiology and provides an establishment method of an in-vitro glial scar forming model. The establishment method of the in-vitro glial scar forming model comprises the steps that purified meninx (meningo) fiber cells and purified astroglia cells are planted in adjacent small cells on a cavity glass slide respectively with a certain amount ratio, and a culture medium is added for culture; after the cells grow in an adherent mode, a partition board between the small cells is removed, and culture continues to be conducted; when it is observed that the meninx (meningo) fiber cells and the astroglia cells grow and come close to each other, mechanical scratching is conducted at the junction of the two kinds of cells so as to damage the cells, and finally, a glial scar structure is formed. The in-vitro glial scar forming model obtained through the method can well simulate the whole forming process of an in-vitro glial scar, the corresponding glial scar form structure and the change relevant to the cytobiology and the molecular biology appear, and an in-vitro cell-level experimental model is provided for studying of the glial scar forming mechanism and relevant treatment.
Owner:南通大学技术转移中心有限公司
Reversibly immortalised olfactory ensheathing glia and their use to promote neuronal regenaration
The present invention is based on the capacity of the Olfactory Ensheathing Glia (OEG) to foster axonal regeneration in the adult mammalian central nervous system (CNS). This specific capacity is probably due to a combination of several factors, such as the molecular composition of cellular membrane and / or the capacity to secrete some molecules; combined with the capacity to reduce glial scar and accompany new growing axon in the damaged CNS. We have developed immortalised cell lines from primary human OEGs. The cells were cultured from post-mortem human tissue from donors and immortalised using a reversible system. Some of these OEG human clonal cell lines were selected by their ability to promote axonal regeneration from adult rat retinal ganglion neurons in a similar fashion to primary OEGs. These cell lines, alone or in pharmaceutical compositions comprising these cells, may be used to repair neuronal damage in the CNS.
Owner:CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) +1
Method utilizing surface microstructure to activate neural astrocyte
ActiveCN105647868AAvoid glial scarsNervous disorderNervous system cellsNervous systemReactive hyperplasia
The invention provides a method utilizing a surface microstructure to activate neural astrocyte, and belongs to the technical field of cell culture. The method comprises the following steps: (1) obtaining a PDMS cell culture surface with an uneven microstructure; (2) adopting primarily cultured neurogliocyte as the activation object, and after the cells grow to the phase of cell fusion, digesting cells by pancreatin (0.25%) to prepare cell suspension; (3) adding the cell suspension to the microstructure surface, and after cell attachment, culturing the cells for 1 to 14 days; (4) identifying the neural astrocyte obtained by the method mentioned above to find a series of activation expressions that cells carry out EMT conversion, cell stem property is enhanced, and glucose transportation is strengthened. The method has the advantage that a physical microstructure on the surface of a culture medium is utilized to activate neural astrocyte and at the same time, formation of glial scar caused by reactive hyperplasia of colloid cells can be avoided. The provided method has a wide application prospect in the treatment of destructive disease and degenerative disease of nervous system.
Owner:DALIAN INST OF CHEM PHYSICS CHINESE ACAD OF SCI
Injectable hydrogel for treating central nervous injury and preparation method thereof
ActiveCN112933293APromote regenerationReduce formationPharmaceutical delivery mechanismTissue regenerationSpinal cord lesionArginine
The invention provides in-situ injectable hydrogel for treating central nervous injury and a preparation method of the in-situ injectable hydrogel. The hydrogel is formed by performing click chemical coupling on X-Y through functional groups on arginine-glycine-aspartic acid modified multi-arm polyethylene glycol-X and multi-arm polyethylene glycol-Y, nano / micron particles and growth factors of slow-release immunoregulation and / or antioxidant drugs loaded on the hydrogel through chemical coupling reaction are coated in the hydrogel. The injection hydrogel disclosed by the invention can be used for precisely and slowly releasing the immunomodulatory and / or antioxidant drug and the growth factor locally at an injured part, so that the formation of a cystic cavity after spinal cord injury is prevented, secondary injury caused by neuroinflammation is relieved, residual spinal cord nervous tissues and axons are protected, and the formation of glial scar tissues is reduced; a penetrable extracellular matrix environment is provided for regeneration of body nerve axons, further recovery of electrophysiology and motor functions is promoted, and the method can be used for repairing injury of soft tissues such as spinal cords and the like.
Owner:ZHEJIANG UNIV
Application of neural stem cells combined with umbilical cord mesenchymal stem cells in spinal cord injury
PendingCN113712995APromote repairReduce areaCell dissociation methodsNervous disorderTissue repairSpinal cord lesion
According to the invention, human induced pluripotent stem cells are differentiated into NSCs in vitro, human umbilical cords are separated and cultured into MSC auxiliary materials, the materials are used according to the proportion of 1: 1, PBS is used as a solvent, an obtained cell biological product is jointly transplanted to the spinal cord of a mouse with acute spinal cord injury (at the thoracic marrow T10 stage) in situ, nerve injury repair is effectively promoted, and the motor function is improved. The product for treating animal acute spinal cord injury can be differentiated into neurons and glial cells in the host body, reduce the glial scar area, reduce fibrosis and reduce the inflammation level, so that the animal motor function, especially limb coordination, is improved, and the product fully plays a role in subsequent treatment of the spinal cord injury and promotion of tissue repair.
Owner:HEBEI MEDICAL UNIVERSITY
Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein
ActiveUS7576065B2Addition is acceleratedPromotes differentiationBiocideVectorsProgenitorEpendymal Tissue
The present invention relates to a method of inducing neuronal production in a subject, a method of recruiting neurons to a subject's brain, and a method of treating a neurodegenerative condition by administering a neurotrophic factor and an inhibitor of pro-gliogenic bone morphogenetic proteins. Also disclosed is a method of suppressing astrocyte generation and inducing neuronal production in a subject, a method of treating a neurologic condition, and a method of suppressing glial scar formation in a subject by administering an inhibitor of pro-gliogenic bone morphogenetic proteins. Finally, the present invention involves a method of introducing a heterogeneous protein into a subject's brain and spinal cord by introducing a nucleic acid molecule encoding the heterogeneous protein introduced into the subject's ependyma, permitting the protein from the nucleic acid molecule to be expressed within the subject's ependyma, and permitting the expressed protein to migrate within the subject's brain and spinal cord.
Owner:CORNELL RES FOUNDATION INC +1
A preparation method, kit and application of human oligodendrocyte progenitor cells that inhibit secondary nerve injury
ActiveCN106011173BInhibition of secondary damageProtect physiological functionNervous disorderNeuregulinsGlial Growth FactorTherapeutic effect
The invention provides a preparation method of a human oligodendrocyte precursor cell inhibiting nerve secondary. Specifically, the method includes: constructing a virus expression vector of two glial growth factors, conducting cotransfection of a human oligodendrocyte precursor cell to prepare the human oligodendrocyte precursor cell, which can achieve high expression of the two glial growth factors, i.e. a growth related factor 43 and a glial growth factor 2, give play to the combined action of the two to promote oligodendrocyte repair, and inhibit nerve secondary injury caused by proliferative response and glial scar formation after oligodendrocyte injury. Also, the proliferation and differentiation ability of oligodendrocyte precursor cell itself is also utilized to participate in nerve function repair, and no tumorigenesis exists. The invention also provides a kit for preparation of the human oligodendrocyte precursor cell inhibiting nerve secondary. The human oligodendrocyte precursor cell provided by the invention has very good therapeutic effect on nervous system diseases.
Owner:江西美奥生物技术有限公司
The application of mir containing the specific seed base sequence at the 5' end, the improved Schwann cell and its application
ActiveCN109694882BAchieve regenerationImproved incompatibility integrationNervous disorderGenetically modified cellsNeurotrophic factorsExpression gene
The invention provides an application of a miR containing a 5'- terminal specific seed base sequence, an improved Schwann cell and applications thereof, and relates to the technical field of central nervous system damage repairing. The miR is used to promote the compatibility and integration between Schwann cells and astrocyte; and the 5'- terminal specific seed base sequence is UAAGGCAC or AAGGCAC. The results of experiments show that after the expression level of matured miR containing a 5'- terminal specific seed base sequence is artificially improved, the expression of astrocyte related gene in improved Schwann cells is obviously reduced, the expression of neurotrophic factor genes (NT-3 and BDNF) is obviously increased, and improved Schwann cells are compatible with and fused with astrocyte. The improved Schwann cells can inhibit astrocyte, the integration of Schwann cells and astrocyte is promoted, and the formation of glial scars caused by astrocyte is inhibited.
Owner:JILIN UNIV
Glioma cell exosomes containing mir-124 and preparation method and application thereof
ActiveCN113082216BReduce formationWeakened ability to formCell dissociation methodsOrganic active ingredientsDiseaseCholesterol
Owner:JILIN UNIV
Western medicine compound for treatment of spinal cord injury and use thereof
InactiveCN106580969AImprove BBB ratingDosing window is wideOrganic active ingredientsNervous disorderTreatment effectMass ratio
The invention discloses a Western medicine compound for treatment of spinal cord injury and a use thereof. The Western medicine compound is composed of gabexate mesylate and nitrofurantoin, wherein the mass ratio of gabexate mesilate to nitrofurantoin is (0.09-0.13) to 1. When the Western medicine compound is applied to the treatment of spinal cord injury, the adult injection dosage of the Western medicine compound is 1.9-2.1 mg / kg, and the drug administration is performed 6-12 h later after spinal cord injury. Through test treatment of a spinal cord injury modeling animal, the Western medicine compound is found out to reduce cell apoptosis, promote nerve cell survival, inhibit formation of glial scar and significantly improve BBB scores of the animal after treatment, and the Western medicine compound is indicated to have a significant effect on promoting motion function recovery after spinal cord injury. Compared with a commonly used drug methylprednisolone for treating spinal cord injury in clinic at current, the Western medicine compound has the advantages of wider drug administration window, more lasting treatment effect and better long-term effect.
Owner:ZHENGZHOU ZHENGXIAN PHARMA CO LTD
Pharmaceutical application of nafamostat
ActiveCN103479612BImprove BBB ratingReduce apoptosisOrganic active ingredientsNervous disorderMethylprednisoloneApoptosis
The invention provides application of nafamostat in preparation of a medicament for treating spinal cord injury. The nafamostat is applied to therapeutic intervention of the spinal cord injury, and experiments show that the nafamostat can reduce apoptosis of cells, promote survival of neurons, inhibit formation of glial scars and remarkably improve the BBB score of a treated animal. Compared with a methylprednisolone medicament applied clinically at present, the nafamostat has the advantages of wider administration window, more lasting treatment effect and better long-term effect.
Owner:冯世庆
Use of a compound in repairing nerve injury
ActiveUS10702524B2Reduce productionLower Level RequirementsOrganic active ingredientsNervous disorderPharmaceutical drugCytokine
Owner:FENG SHIQING +1
Western medicine composition for treating spinal cord injury, and application of composition
InactiveCN106580974AImprove BBB ratingDosing window is wideNervous disorderHeterocyclic compound active ingredientsTreatment effectMass ratio
The invention discloses a western medicine composition for treating spinal cord injury, and an application of the composition. The western medicine composition consists of hexoprenaline and sulbactam, wherein a mass ratio of hexoprenaline to sulbactam is (0.17-0.22) : 1; and when the western medicine composition is used for treating the spinal cord injury, an injection dose for adults is 0.95-1.00mg / kg, and the administration time is 6-24 hours after the spinal cord injury. Through test treatment of a model of an animal with spinal cord injury, it is discovered that the western medicine composition can reduce cell apoptosis, facilitate neuronal survival, inhibit glial scar formation and remarkably improve a BBB score of the treated animal, so that the western medicine composition has a remarkable promotion effect for motor function recovery after the spinal cord injury. Compared with an existing common medicine-methylprednisolone used for treating the spinal cord injury in clinic, the western medicine composition has the advantages that an administration window is wider, the treatment effect is more lasting, and the long-term effect is better.
Owner:ZHENGZHOU ZHENGXIAN PHARMA CO LTD
An in vitro glial scar formation model and its construction method and application
ActiveCN104911140BEasy to makeLow costMicrobiological testing/measurementNervous system cellsIn vivoCell
The invention belongs to the technical field of cell biology. The invention provides a method for constructing an in vitro glial scar formation model, which comprises purifying the purified cerebellar (spinal) membrane fibroblasts and astrocytes in a certain quantitative ratio. Planted in adjacent small chambers on chamber slides, culture medium was added; when the cells adhered to the wall, the partitions between small chambers were removed, and the culture was continued; when brain (spinal) membrane fibroblasts and When these two types of cells grow and approach each other, astrocytes use a sharp instrument to make mechanical scratches at the junction of the two types of cells to damage the cells, eventually forming a glial-like scar structure. The in vitro glial scar formation model obtained by the present invention can better simulate the whole process of in vivo glial scar formation, and the corresponding morphological structure of the glial scar and the changes of related cell biology and molecular biology appear, which is called glial scar formation. Mechanism studies and related therapeutic studies provide experimental models at the cellular level in vitro.
Owner:南通大学技术转移中心有限公司
Method of Using Fish Plasma Components to Inhibit Glial Scarring and Promote Functional Recovery in the Mammalian CNS
InactiveUS20090124548A1Enhanced inhibitory effectMeasurable and significant functional recoveryNervous disorderPeptide/protein ingredientsNervous systemMedicine
A method includes applying salmon fibrin at a central nervous system injury site. For example, applying salmon fibrin can include injecting salmon fibrin. The method can also include causing the suppression of astrocyte activation, whereby glial scarring is at least reduced. The functional recovery of a patient who has suffered a central nervous system injury is promoted according to this method.
Owner:SAWYER EVELYN S
Western medicine compound for treating fracture
InactiveCN106511987AImprove BBB ratingDosing window is wideOrganic active ingredientsPeptide/protein ingredientsTreatment effectMass ratio
The invention discloses a western medicine compound for treating fracture. The western medicine compound consists of ulinastatin and levofloxacin, wherein the mass ratio of the ulinastatin to the levofloxacin is 0.09-0.13: 1; when the western medicine compound is used for treating the fracture, the injected dose of the western medicine compound for adults is 1.9-2.1 mg / kg, and the drug administration time is the time of 6-12 hours after fracture. Through testing therapy to fracture molding animals, the western medicine compound can reduce cell apoptosis, promote survival of nerve cells and inhibit formation of glial scar; BBB grade of treated animals is increased remarkably; and the western medicine has remarkable promotion effect on functional recovery of locomotion after fracture. Compared with methylprednisolone as a common drug for treating fracture, the western medicine compound is wider in administration window, is lasting in treatment effect and better in long-term effect.
Owner:HENAN BALING ELECTRONICS TECH CO LTD
A method for activating astrocytes using surface microstructures
ActiveCN105647868BAvoid glial scarsNervous disorderNervous system cellsNervous systemReactive hyperplasia
Owner:DALIAN INST OF CHEM PHYSICS CHINESE ACAD OF SCI
Use of a compound in repairing nerve injury
ActiveUS20190336501A1Reduce productionDecrease in apoptosis levelOrganic active ingredientsNervous disorderNeurophysinsPharmaceutical drug
The present invention falls within the field of medical technology, and in particular relates to the use of a compound as shown in formula (I). In particular, the present invention relates to the use of the compound as shown in formula (I) in the preparation of a pharmaceutical composition for preventing and / or treating a nerve injury, or relieving a nerve injury-associated symptom, and further relates to the use thereof in the preparation of a healthcare product for protecting an injured nerve and / or improving motor function. After a nerve injury has occurred, the compound can reduce the production of pro-inflammatory cytokine, decrease the level of apoptosis, promote the survival of neuron, inhibit the formation of glial scar, and has a significant effect in promoting the recovery of motor function.
Owner:FENG SHIQING +1
Olfactory ensheathing cell photo-curing nerve repair hydrogel as well as preparation method and application thereof
PendingCN114767943AImprove survival rateGood restorativeNervous system cellsCell culture supports/coatingSpinal cord lesionTissue defect
The invention provides a preparation method of olfactory ensheathing cell photocuring nerve repair hydrogel. The preparation method specifically comprises the following steps: preparing a hydrogel composite scaffold; mixing the hydrogel composite scaffold with a DMEM / F-12 culture medium containing fetal calf serum to obtain a composite culture medium; and culturing the olfactory ensheathing cells by using the composite culture medium to obtain the olfactory ensheathing cell light-cured neural restoration hydrogel. Compared with traditional olfactory ensheathing cells, the olfactory ensheathing cell photo-curing nerve repair hydrogel provided by the invention can effectively improve the survival rate of the olfactory ensheathing cells, also can fill spinal cord tissue defects and integrate with peripheral tissues, inhibit inflammatory response and glial scar formation, induce nerve fiber regeneration, and improve the survival rate of the olfactory ensheathing cells. The recovery of the motion function after spinal cord injury can be promoted to a certain extent.
Owner:XI AN JIAOTONG UNIV
Western medicine combination for treating spinal cord injury and application of western medicine combination
InactiveCN106491614AImprove BBB ratingDosing window is wideOrganic active ingredientsNervous disorderMethylprednisoloneTherapeutic effect
The invention discloses a western medicine combination for treating spinal cord injury and application of the western medicine combination. The western medicine combination contains methotrexate and macrodantin, wherein the mass ratio of the methotrexate to the macrodantin is (0.09-0.13):1; when the western medicine combination is applied to treatment on spinal cord injury, the injection dosage of the western medicine combination to an adult is 1.9-2.1mg / kg, and the administration time is 6-12 hours after spinal cord injury. Trail treatment on model animals suffering from spinal cord injury shows that by using the western medicine combination, apoptosis can be reduced, nerve cell survival can be promoted, glial scar formation can be inhibited, BBB scoring of treated animals can be remarkably improved, and the western medicine combination disclosed by the invention has a remarkable promotion function on motor function recovery after spinal cord injury. Compared with a common medicine, namely, methylprednisolone for treating spinal cord injury, the western medicine combination disclosed by the invention is relatively wide in administration window, relatively long-lasting in treatment effect and relatively good in long-term effect.
Owner:ZHENGZHOU ZHENGXIAN PHARMA CO LTD
Reversibly immortalised olfactory ensheathing glia and their use to promote neuronal regeneration
Owner:CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com